- Home
- JANX vs CHCO Comparison
JANX vs CHCO Comparison
Compare JANX & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- CHCO
- Stock Information
- Founded
- JANX 2017
- CHCO 1957
- Country
- JANX United States
- CHCO United States
- Employees
- JANX N/A
- CHCO N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- CHCO Major Banks
- Sector
- JANX Health Care
- CHCO Finance
- Exchange
- JANX Nasdaq
- CHCO Nasdaq
- Market Cap
- JANX 1.6B
- CHCO 1.7B
- IPO Year
- JANX 2021
- CHCO N/A
- Fundamental
- Price
- JANX $23.60
- CHCO $116.32
- Analyst Decision
- JANX Strong Buy
- CHCO Hold
- Analyst Count
- JANX 7
- CHCO 2
- Target Price
- JANX $94.29
- CHCO $127.50
- AVG Volume (30 Days)
- JANX 808.2K
- CHCO 55.6K
- Earning Date
- JANX 08-06-2025
- CHCO 07-22-2025
- Dividend Yield
- JANX N/A
- CHCO 2.72%
- EPS Growth
- JANX N/A
- CHCO 0.39
- EPS
- JANX N/A
- CHCO 7.98
- Revenue
- JANX $9,336,000.00
- CHCO $293,748,000.00
- Revenue This Year
- JANX N/A
- CHCO $6.69
- Revenue Next Year
- JANX $1,470.82
- CHCO $1.78
- P/E Ratio
- JANX N/A
- CHCO $14.55
- Revenue Growth
- JANX 28.12
- CHCO 1.31
- 52 Week Low
- JANX $22.48
- CHCO $102.22
- 52 Week High
- JANX $71.71
- CHCO $137.28
- Technical
- Relative Strength Index (RSI)
- JANX 41.60
- CHCO 45.34
- Support Level
- JANX $24.45
- CHCO $114.78
- Resistance Level
- JANX $27.28
- CHCO $117.12
- Average True Range (ATR)
- JANX 1.35
- CHCO 1.82
- MACD
- JANX -0.09
- CHCO -0.31
- Stochastic Oscillator
- JANX 22.20
- CHCO 32.25
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CHCO City Holding Company
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.